In vivo experiments demonstrated that MORIN treatment significantly upregulated the expression of Parkin and LC3-II in the frontal cortex and hippocampus of Parkinson’s disease (PD) mice, downregulated the expression of Mfn1, increased the expression of tyrosine hydroxylase (TH) protein, facilitated mitophagy, attenuated the loss of dopaminergic neurons, and ameliorated the behavioral deficits in PD mice (Wang ZY. This evidence concerns the gene PRKN and Parkinson disease.